Cover Image

Advances in targeted therapy for acute myeloid leukaemia

In the past few years, research in the underlying pathogenic mechanisms of acute myeloid leukaemia (AML) has led to remarkable advances in our understanding of the disease. Cytogenetic and molecular aberrations are the most important factors in determining response to chemotherapy as well as long-te...

Full description

Saved in:
Bibliographic Details
Main Authors: Kayser, Sabine (Author) , Levis, Mark J. (Author)
Format: Article (Journal)
Language:English
Published: 2018
In: British journal of haematology
Year: 2017, Volume: 180, Issue: 4, Pages: 484-500
ISSN:1365-2141
DOI:10.1111/bjh.15032
Online Access:Verlag, Volltext: http://dx.doi.org/10.1111/bjh.15032
Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.15032
Get full text
Author Notes:Sabine Kayser and Mark J. Levis

MARC

LEADER 00000caa a2200000 c 4500
001 1578065224
003 DE-627
005 20230426230803.0
007 cr uuu---uuuuu
008 180730r20182017xx |||||o 00| ||eng c
024 7 |a 10.1111/bjh.15032  |2 doi 
035 |a (DE-627)1578065224 
035 |a (DE-576)508065224 
035 |a (DE-599)BSZ508065224 
035 |a (OCoLC)1341014630 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Kayser, Sabine  |d 1979-  |e VerfasserIn  |0 (DE-588)138694923  |0 (DE-627)605256233  |0 (DE-576)30778813X  |4 aut 
245 1 0 |a Advances in targeted therapy for acute myeloid leukaemia  |c Sabine Kayser and Mark J. Levis 
264 1 |c 2018 
300 |a 17 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a First published: 28 November 2017 
500 |a Gesehen am 30.07.2018 
520 |a In the past few years, research in the underlying pathogenic mechanisms of acute myeloid leukaemia (AML) has led to remarkable advances in our understanding of the disease. Cytogenetic and molecular aberrations are the most important factors in determining response to chemotherapy as well as long-term outcome, but beyond prognostication are potential therapeutic targets. Our increased understanding of the pathogenesis of AML, facilitated by next-generation sequencing, has spurred the development of new compounds in the treatment of AML, particularly the creation of small molecules that target the disease on a molecular level. Various new agents, such as tyrosine kinase inhibitors, immune checkpoint inhibitors, monoclonal or bispecific T-cell engager antibodies, metabolic and pro-apoptotic agents are currently investigated within clinical trials. The highest response rates are often achieved when new molecularly targeted therapies are combined with standard chemotherapy. Presented here is an overview of novel therapies currently being evaluated in AML. 
534 |c 2017 
650 4 |a acute myeloid leukaemia 
650 4 |a BCL-2 inhibitor 
650 4 |a immune-checkpoint inhibitors 
650 4 |a targeted therapy 
650 4 |a tyrosine kinase inhibitors 
700 1 |a Levis, Mark J.  |e VerfasserIn  |0 (DE-588)1163573825  |0 (DE-627)1027896227  |0 (DE-576)508064465  |4 aut 
773 0 8 |i Enthalten in  |t British journal of haematology  |d Oxford [u.a.] : Wiley-Blackwell, 1955  |g 180(2018), 4, Seite 484-500  |h Online-Ressource  |w (DE-627)269758941  |w (DE-600)1475751-5  |w (DE-576)09113997X  |x 1365-2141  |7 nnas  |a Advances in targeted therapy for acute myeloid leukaemia 
773 1 8 |g volume:180  |g year:2018  |g number:4  |g pages:484-500  |g extent:17  |a Advances in targeted therapy for acute myeloid leukaemia 
856 4 0 |u http://dx.doi.org/10.1111/bjh.15032  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.15032  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180730 
993 |a Article 
994 |a 2018 
998 |g 138694923  |a Kayser, Sabine  |m 138694923:Kayser, Sabine  |d 910000  |d 910100  |e 910000PK138694923  |e 910100PK138694923  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1578065224  |e 3019739365 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"title":"Advances in targeted therapy for acute myeloid leukaemia","title_sort":"Advances in targeted therapy for acute myeloid leukaemia"}],"person":[{"family":"Kayser","roleDisplay":"VerfasserIn","role":"aut","given":"Sabine","display":"Kayser, Sabine"},{"roleDisplay":"VerfasserIn","role":"aut","family":"Levis","given":"Mark J.","display":"Levis, Mark J."}],"name":{"displayForm":["Sabine Kayser and Mark J. Levis"]},"origin":[{"dateIssuedDisp":"2018","dateIssuedKey":"2018"}],"relHost":[{"name":{"displayForm":["ed. R. B. Thompson [u.a.]"]},"titleAlt":[{"title":"the official journal of the British Society of Haematology"},{"title":"BJH ; the official journal of the British Society for Haematology"}],"title":[{"title":"British journal of haematology","subtitle":"BJHaem : an official journal of the British Society for Haematology","title_sort":"British journal of haematology"}],"language":["eng"],"recId":"269758941","origin":[{"publisherPlace":"Oxford [u.a.] ; Oxford ; Oxford [u.a.]","dateIssuedDisp":"1955-","dateIssuedKey":"1955","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell"}],"part":{"issue":"4","volume":"180","pages":"484-500","extent":"17","text":"180(2018), 4, Seite 484-500","year":"2018"},"note":["Gesehen am 08.05.08"],"disp":"Advances in targeted therapy for acute myeloid leukaemiaBritish journal of haematology","corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"British Society for Haematology"},{"display":"European Hematology Association","role":"isb","roleDisplay":"Herausgebendes Organ"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["1475751-5"],"eki":["269758941"],"doi":["10.1111/(ISSN)1365-2141"],"issn":["1365-2141"]},"pubHistory":["1.1955 -"],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["First published: 28 November 2017","Gesehen am 30.07.2018"],"physDesc":[{"extent":"17 S."}],"language":["eng"],"recId":"1578065224","id":{"doi":["10.1111/bjh.15032"],"eki":["1578065224"]}} 
SRT |a KAYSERSABIADVANCESIN2018 

Similar Items